ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Telmisartan (Primary) ; Ramipril
- Indications Angina pectoris; Cardiovascular disorders; Hypertension; Intermittent claudication; Left ventricular hypertrophy; Unstable angina pectoris
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms TRANS; TRANSCEND
- Sponsors Boehringer Ingelheim
- 28 Mar 2019 Results of pooled post hoc analysis from ONTARGET/TRANSCEND studies assessing cardiovascular outcomes and achieved blood pressure published in the European Heart Journal.
- 24 Dec 2018 Results assessing resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals from ONTARGET and TRANSCEND trials, published in the European Heart Journal.
- 01 Jul 2015 Results published in the Journal of Internal Medicine.